Halozyme Targets Up To $1.925 Billion In Sales As Quarterly Royalties Grow 44%

The drug-delivery company raised its earnings outlook and completed $400 million in buybacks; shares fell about 4% in Friday trading.

Share
Halozyme Targets Up To $1.925 Billion In Sales As Quarterly Royalties Grow 44%

Halozyme Therapeutics, which licenses technology that lets drug makers replace intravenous infusions with under-the-skin injections, raised its 2026 sales forecast Thursday to $1.860–$1.925 billion. Its earnings statement, released with an SEC filing, put third-quarter royalties at $341.0 million, up 44% from a year earlier.

Partner Drugs Drive Royalty Growth

Third-quarter revenue rose 39% to $493.0 million from $354.3 million a year earlier, with royalties and product sales supplying the growth. Halozyme attributed the royalty increase from $236.0 million mainly to sales of argenx’s VYVGART Hytrulo, Janssen’s DARZALEX SC and Roche’s Phesgo.

Operating income reached $295.0 million, against $217.9 million a year earlier. Net income rose to $247.0 million from $175.2 million, and diluted earnings increased to $2.01 per share from $1.43. Adjusted earnings were $2.39 per share, compared with $1.72.

HALO shares fell about 4% to $117.89 in Friday trading. The higher forecasts and quarterly growth were reported Thursday.

Higher Forecasts Include Technology Spending

The new sales range replaces $1.835–$1.910 billion and implies growth of 33%–38% over 2025. Halozyme also lifted its royalty outlook to $1.235–$1.255 billion from $1.220–$1.245 billion, putting expected annual royalty growth at 42%–45%.

Management now expects adjusted earnings of $8.75–$9.05 per share, versus $8.65–$9.00 previously. Its forecast for adjusted earnings before interest, taxes, depreciation and amortization rose to $1.240–$1.290 billion from $1.225–$1.280 billion. Both earnings forecasts include approximately $60 million of investment in Hypercon and Aerocon; the per-share outlook excludes potential future buybacks.

The technology expansion carries costs. Research spending reached $27.8 million, versus $17.3 million a year earlier, chiefly because of the purchases of Elektrofi in November 2025 and Surf Bio in the fourth quarter of 2025. Halozyme also attributed higher intangible-asset amortization—$29.5 million versus $17.8 million—to Elektrofi.

Halozyme earns license fees, milestones, enzyme sales and royalties through ENHANZE. Hypercon and Surf Bio’s technology, renamed Aerocon, are intended to concentrate drugs into smaller injection volumes. The company also makes auto-injectors and sells Hylenex and XYOSTED.

Buybacks And A Larger Cash Balance

Cash, cash equivalents, restricted cash and marketable securities totaled $1.08 billion on September 30, 2026, compared with $145.4 million at year-end 2025. Convertible-note issuance and operating cash generation were the principal sources of the increase.

Darren Snellgrove, Halozyme’s executive vice president and chief financial officer, said the company completed a $1.5 billion convertible-note financing. He also said, “We completed $400 million in share repurchases this year while continuing to invest in our highest-return organic opportunities and maintaining a clear path to retire our remaining 2027 and 2028 notes at maturity.”

Third-quarter buybacks accounted for $67.2 million, purchasing approximately 0.8 million shares at an average $79.47 each under the May 2026 program.

Halozyme’s stated debt-repayment plan remains tied to the remaining notes’ 2027 and 2028 maturities.

Sources

More on Halozyme Therapeutics

All Halozyme Therapeutics (HALO) coverage →